Skip to Content
Merck
HomeApplicationsChemistry & SynthesisTargeted Protein Degradation

Targeted Protein Degradation

3D model of a co-crystal structure with the PROTAC in green binding to the target in yellow and the E3 ubiquitin in pink for targeted protein degradation.

Targeted protein degradation (TPD) is a novel drug discovery strategy that eradicates problem proteins from cells by hijacking cellular degradation processes with small molecules. One of these processes is the ubiquitin-proteasome pathway, an intracellular quality control mechanism that utilizes E3 ubiquitin ligases and associated partners to seek out damaged or misfolded proteins for degradation via the proteasome or “cellular trash can.” Proteolysis-targeting chimeras (PROTAC® degraders) are heterobifunctional molecules containing a disease target warhead and E3 ligase ligand tethered together by a linker. 

When added to cells, they recruit the target protein to the E3 ligase, hijacking the native degradation pathway to remove the disease target. This protein silencing approach delivers phenotypes that have been called the chemical equivalent to CRISPR – yet with small-molecule control. 



Featured Categories

Proteases for Research Applications
Proteases

Protease reagents and resources for endo- and exopeptidase cleavage application needs and resources for your protein cleavage workflow.

Shop Products
Duolink<sup>®</sup> Proximity Ligation Assay
Duolink® Proximity Ligation Assay

Duolink® Proximity Ligation Assay (PLA) technology for detecting and quantifying protein-protein interactions.

Shop Products
Person wearing a labcoat, gloves, and protective glasses using an Assurance® GDS PickPen™ concentration device for PCR pathogen detection
Pathogen Screening Kits, Instruments & Disposables

Pathogen testing is a key component and critical success factor in effective food safety and process control programs.

Shop Products
Illustration of a ribosome moving along mRNA to incorporate amino acids into a polypeptide.
Amino Acids

We have a comprehensive offering of high-purity amino acids and derivatives important to metabolomic pathways...

Shop Products

PROTAC®-mediated degradation of a target provides many advantages to traditional occupancy-based inhibition by small molecules. Degraders developed from leads, warheads, or inhibitors demonstrate improved cellular responses and target selectivity. As the degrader is not eliminated alongside the target, it is recycled, operating catalytically at lower doses. Lastly, where ~80% of protein targets have been deemed intractable to traditional small molecules due to a lack of defined binding cavities or active sites (“undruggables”), lower affinity binders have been successfully developed into successful degraders by their ability to recruit diverse targets to an E3 ligase. Due in part to these reasons, protein degraders have been identified as new modalities in drug discovery and hold a promising future as research tools.

As protein degraders interact with both a target protein and E3 ligase simultaneously, their design is not trivial. A modular approach is often taken to generate PROTAC® libraries to screen for degradation of target proteins. To do this, strategic permutations of E3 ligands, target warheads, and linkers are synthesized with growing attention to linker properties and exit vectors. Each member of the target-specific degrader library is analyzed for depletion of the target in cells, providing leads for further optimization and characterization.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Document Search
Looking for More Specific Information?

Visit our document search for data sheets, certificates and technical documentation.

Find Documents


    Sign In To Continue

    To continue reading please sign in or create an account.

    Don't Have An Account?